Design
Review
Authors
Loading...
May support preferring moxonidine or rilmenidine to limit somnolence; leaves open head-to-head RCTs versus nonselective agents.
Selective imidazoline-receptor agonists like moxonidine and rilmenidine may offer antihypertensive efficacy with fewer side effects like somnolence compared to non-selective agents.
Donald J. Reis (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: